Clinical Trial Update: Study to Evaluate the Safety and Immunogenicity of Investigational Vaccines Using the RSV (Respiratory Syncytial Virus) Monovalent Antigen in Healthy Participants 18 to 49 Years of Age [Phase 1]

View source ↗

Summary

A Phase 1 trial update evaluating safety and immunogenicity of investigational vaccines using the RSV monovalent antigen in healthy adults 18 to 49; the study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• RSV Monovalent Antigen Investigational Vaccine (RSV monovalent antigen vaccine)

Snippet

Sponsor: Sanofi | Conditions: Respiratory Syncytial Virus Immunization | Phase 1 | Status: ACTIVE_NOT_RECRUITING